FT-573

N/A

Report date: 2022/09/06 18:12:14

Base Information

Drug NameFT-573
Drug Alias NameFT-573
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor III-A agonistsInterleukin-15 modulatorsCD276 antigen inhibitors
TargetsLow affinity immunoglobulin gamma Fc region receptor III-AInterleukin-15CD276 antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of MinnesotaFate Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Minnesota
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A